IL2102

IL2102 is a small molecule inhibitor targeting Son of Sevenless homolog 1 (SOS1), currently under development by iLeadBMS for the treatment of RAS-driven cancers. SOS1 is a guanine nucleotide exchange factor (GEF) that facilitates the transition of RAS from its inactive GDP-bound state to its active GTP-bound state. By inhibiting SOS1, IL2102 aims to disrupt the activation of RAS and its downstream signaling pathways, such as the MAPK/ERK pathway, which are frequently mutated and constitutively active in various malignancies including lung, colorectal, and pancreatic cancers. This approach is designed to provide a therapeutic option for patients with KRAS, NRAS, or HRAS mutations by targeting the common activator of these proteins.